Mallinckrodt medical sales rise 15% in third quarter:
This article was originally published in Clinica
Executive Summary
Mallinckrodt Medical has reported third-quarter sales of $255.5 million, 15% higher than a year earlier. Mallinckrodt says that its medical division had strong sales in all areas despite continuing downward pressure from healthcare cost reduction efforts. In the first nine months of fiscal 1995 sales rose 12% to $725.7 million. Mallinckrodt's group sales were up 17% to $569.1 million in the third quarter (ended March 31st). Net income improved to $47 million compared with $42.3 million in the same 1994 period.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.